Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 18;10(1):8191.
doi: 10.1038/s41598-020-65238-z.

A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapy

Jordan Hart  1   2   3 , Briohny Spencer  1   2   3 , Catherine M McDermott  4   3 , Russ Chess-Williams  4   3 , Donna Sellers  4   3 , David Christie  2   5   3 , Shailendra Anoopkumar-Dukie  6   7   8
Affiliations

A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapy

Jordan Hart et al. Sci Rep. .

Abstract

While alpha-blockers are commonly used to reduce lower urinary tract symptoms in prostate cancer patients receiving radiotherapy, their impact on response to radiotherapy remains unknown. Therefore, this pilot study aimed to retrospectively determine if alpha-blockers use, influenced response to radiotherapy for localised prostate cancer. In total, 303 prostate cancer patients were included, consisting of 84 control (alpha-blocker naïve), 72 tamsulosin and 147 prazosin patients. The main outcomes measured were relapse rates (%), time to biochemical relapse (months) and PSA velocity (ng/mL/year). Recurrence free survival was calculated using Kaplan-Meier analysis. Prazosin significantly reduced biochemical relapse at both two and five-years (2.72%, 8.84%) compared to control (22.61%, 34.52%). Recurrence free survival was also significantly higher in the prazosin group. This remained after multivariable analysis (HR: 0.09, 95% CI: 0.04-0.26, p < 0.001). Patients receiving prazosin had a 3.9 times lower relative risk of biochemical relapse compared to control. Although not statistically significant, tamsulosin and prazosin extended recurrence free survival by 13.15 and 9.21 months respectively. We show for the first time that prazosin may reduce risk of prostate cancer recurrence and delay time to biochemical relapse and provides justification for prospective studies to examine its potential as an adjunct treatment option for localised prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Kaplan Meier plot of recurrence free survival (%) in control, tamsulosin and prazosin treatment groups for a period of 120 months (10 years).
See this image and copyright information in PMC

References

    1. Australian Institute of Health and Welfare. Prostate Cancer, http://www.aihw.gov.au/cancer/prostate/ (2017).
    1. Sieh W, et al. Treatment and Mortality in Men with Localized Prostate Cancer: A Population-Based Study in California. The open prostate cancer journal. 2013;6:1–9. doi: 10.2174/1876822901306010001. - DOI - PMC - PubMed
    1. Di Lorenzo G. Castration-Resistant Prostate Cancer Current and Emerging Treatment Strategies. Drugs (New York, N.Y.) 2010;70:983–1000. - PubMed
    1. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. International journal of clinical practice. 2011;65:1180–1192. doi: 10.1111/j.1742-1241.2011.02799.x. - DOI - PubMed
    1. Delaney, G. Radiotherapy in cancer care: estimating the optimal utilization from a review of evidence-based clinical guidelines, University of New South Wales, (2007). - PubMed

Publication types

Substances